Klinikum der Ludwig-Maximilians-Universitaet Muenchen

München 81377

7 studies enrolling now · 10 studies all time

What they study most

Angelman Syndrome, Breast Neoplasms, Colorectal Cancer, DM1, FSH Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Dystrophy, Facioscapulohumeral Muscular Dystrophy

Studies at this site

• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer — Recruiting now
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) — Recruiting now
• REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome — Recruiting now
• A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD — Recruiting now
• Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) — Recruiting now
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 — Enrolling by invitation
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) — Stopped early
• Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer — Completed